China Resources Shuanghe (600062.SH) passed the drug GMP compliance inspection

Zhitongcaijing · 1d ago

Zhitong Finance App News, China Resources Shuanghe (600062.SH) issued an announcement. Recently, the company received the “Drug GMP Compliance Inspection Notice” issued by the Beijing Drug Administration. The inspection scope and related workshops and production lines of this GMP inspection are: ① amlodipine benazepril capsules, specifications: 5 mg of amlodipine sulfonate per capsule (based on amlodipine) and 10 mg benazepril hydrochloride (solid formulation workshop hard capsule production line); ② powder (compound polyethylene glycol (3350) electrolyte dispersion, specifications: 6.9g/bag, powder production line in the solid preparation workshop, produced in-house). The inspection period is from September 8, 2026 to September 11, 2026. The company passed the drug GMP compliance inspection this time, indicating that the company's product production quality management meets GMP requirements, which will help the company continue to maintain stable product quality and continuous stable production capacity to meet the market demand for related pharmaceuticals.